ABIOMED (ABMD) and Cogentix Medical (CGNT) Financial Contrast

ABIOMED (NASDAQ: ABMD) and Cogentix Medical (NASDAQ:CGNT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Risk & Volatility

ABIOMED has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Cogentix Medical has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.

Valuation & Earnings

This table compares ABIOMED and Cogentix Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ABIOMED $445.30 million 28.48 $52.11 million $1.98 144.64
Cogentix Medical $51.85 million 4.50 -$22.09 million ($0.41) -9.34

ABIOMED has higher revenue and earnings than Cogentix Medical. Cogentix Medical is trading at a lower price-to-earnings ratio than ABIOMED, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for ABIOMED and Cogentix Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABIOMED 0 2 6 0 2.75
Cogentix Medical 0 1 2 0 2.67

ABIOMED currently has a consensus target price of $301.50, suggesting a potential upside of 5.28%. Cogentix Medical has a consensus target price of $4.58, suggesting a potential upside of 19.67%. Given Cogentix Medical’s higher possible upside, analysts plainly believe Cogentix Medical is more favorable than ABIOMED.


This table compares ABIOMED and Cogentix Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ABIOMED 16.58% 15.54% 13.40%
Cogentix Medical -36.14% -11.52% -10.04%

Insider and Institutional Ownership

88.4% of ABIOMED shares are owned by institutional investors. Comparatively, 14.5% of Cogentix Medical shares are owned by institutional investors. 7.0% of ABIOMED shares are owned by insiders. Comparatively, 62.7% of Cogentix Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


ABIOMED beats Cogentix Medical on 10 of the 13 factors compared between the two stocks.

ABIOMED Company Profile

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Cogentix Medical Company Profile

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply